Alzheimer'S Disease Clinical Trials in Long Beach, CA

Alzheimer'S Disease Clinical Trials in Long Beach, CA

View the best 10 alzheimer's disease medical studies in Long Beach, California. Access promising new therapies by applying to a Long Beach-based Alzheimer'S Disease clinical trial.

Trials in Long Beach, California

Here are the top 10 medical studies for alzheimer's disease in Long Beach, California

Image of Center for Cognitive Health in Portland, United States.

ATH-1017

Recruiting1 awardPhase 2 & 3
This trial is testing the safety and tolerability of fosgonimeton in Alzheimer's patients who have completed other studies.
Image of Linfritz Research Institute Inc. in Coral Gables, United States.

Piromelatine 20 mg +1 More

Melatonin Receptor Agonist

Recruiting0 awardsPhase 2 & 3
This trial tests piromelatine, a pill taken before bed, in people with mild Alzheimer's who lack a specific genetic variation. The goal is to see if it can improve brain function and slow down dementia progression.
Image of MD First Research - Chandler in Chandler, United States.

Donanemab

Monoclonal Antibodies

Recruiting1 awardPhase 3
This trial is testing different doses of donanemab, a drug aimed at helping people with early Alzheimer's disease. Donanemab has shown rapid reduction of brain amyloid in early Alzheimer's disease. The study will look at how often and how severely participants experience a side effect involving brain swelling. Researchers also want to find out which patient characteristics might predict this side effect.
Image of Clinical Research Site in Toms River, United States.

AXS-05 +1 More

NMDA receptor antagonist

Verified
Recruiting1 awardPhase 3
This trial is testing a new medication called AXS-05 to see if it can help reduce agitation in people with Alzheimer's disease. The goal is to find out if AXS-05 can balance brain chemicals to calm agitation and improve behavior. AXS-05, a combination of dextromethorphan and bupropion, is being investigated for its potential to treat agitation in Alzheimer's disease and has shown promise in early clinical trials.
Image of Barrow Neurological Institute in Phoenix, United States.

Sensory Stimulation System (GS120)

Behavioural Intervention

Recruiting1 award
This trial is an extension of a previous study where participants will receive treatment with an Active Sensory Stimulation System for up to 12 months. There will be no sham treatment or randomization in this
Image of Xenoscience, Inc. in Phoenix, United States.

ALZ-801

Anti-amyloid agent

Recruiting2 awardsPhase 3
"This trial is looking at how safe and effective ALZ-801 is for people with Early Alzheimer's disease who have a specific genetic marker. Participants will receive treatment with ALZ-801 in an open
Image of University of California, San Francisco in San Francisco, United States.

Care Ecosystem

Behavioral Intervention

Recruiting1 award10 criteria
This trial will evaluate how an accessible, team-based dementia care program can improve outcomes for patients, caregivers, and healthcare providers during the pandemic.
Image of MD First Research - Chandler in Chandler, United States.

BMS-986446

Monoclonal Antibodies

Recruiting0 awardsPhase 2
This trial is testing a new medication called BMS-986446 in people with early Alzheimer's disease. The medication is designed to target harmful proteins in the brain to slow down the disease. Researchers are checking if it works well and is safe for patients.
Image of Brain Matters Research in Delray Beach, United States.

Sensory Stimulation System (GS120) - Active +1 More

Behavioural Intervention

Verified
Recruiting0 awards1 criteria
This trial is testing a device that uses light and sound to help patients with mild to moderate Alzheimer's disease. The goal is to see if this sensory stimulation can slow down the progression of the disease by improving brain function. This therapy has shown potential for application in the treatment of Alzheimer's disease.
Image of Clinical Site in Anaheim, United States.

ITI-1284

Behavioural Intervention

Recruiting0 awardsPhase 2
This trial is testing a new medication called ITI-1284 to see if it is effective, safe, and well-tolerated in treating psychosis in patients with Alzheimer's disease.

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.